Collection of Biospecimen & Clinical Information in Patients w/ Gastrointestinal Cancers
Gastrointestinal NeoplasmsGynecologic Cancers12 moreWe have an active research program in gastrointestinal cancers including clinical trials, epidemiologic, and translational studies. We would like to establish a biospecimen bank linked to useful clinical information in order to learn more about diagnostic, predictive and prognostic markers for gastrointestinal cancers. PRIMARY OBJECTIVES: 1. To collect and store tumor and normal tissue (previously collected paraffin embedded or frozen specimen) and blood in patients with gastrointestinal (GI) cancers. SECONDARY OBJECTIVES: Collect detailed clinical information via a patient questionnaire that includes demographic, socioeconomic, lifestyle, family, past medical, medication and cancer histories Collect details about the tumor specimen extracted from patient charts.
International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric...
Metastatic Gastric CancerMetastatic Adenocarcinoma of the Gastroesophageal JunctionThe treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the compassionate use program.
Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors
Esophageal NeoplasmAdenocarcinoma of the Gastroesophageal Junction8 moreAn Expanded Access Protocol for use of DKN-01 for the treatment of advanced solid tumors.
Liquid Biopsy in Monitoring the Therapeutic Efficacy of Targeted Therapy in Advanced/Metastatic...
Gastric CancerTo evaluate the clinical significance of cell free DNA (cfDNA) and circulating tumor cells (CTCs) in real-time monitoring the therapeutic response during HER2-targeted therapy in histologically confirmed HER2 positive advanced/metastatic gastric cancer.
Impact of Adjuvant FOLFOX on Quality of Life and Sensory Neurotoxicity in Patients With Advanced...
Stomach NeoplasmsThe primary objective of this trial is to determine the impact of the FOLFOX regimen on quality of life and the incidence of chemotherapy induced neurotoxicity.
Comparing the Diagnostic Role of PET/MRI and of PET/CT Among Patients With Gastric Cancer
Gastric Cancer StageThe results of PET/MRI and PET/CT in each recruited gastric cancer patients will be compared.
Application Value of CTCs Detection for Advanced Gastric Cancer Patients
Circulating Tumor CellsGastric CancerEvaluating the application value of a new circulating tumor cell detection method for advanced gastric cancer patients in prediction of the prognosis and early evaluation of the result of postoperation adjuvant chemotherapy.
Difference of Gastric Microbiota in the Process of Correa's Model.
Gastric MicrobiotaNon-atrophic Gastritis5 moreHelicobater pylori plays an important role in the development of gastric cancer. Eradication therapy can reducing the morbidity of gastric cancer, but can't totally prevent it especially when atrophy and more serious precancerous lesions already happened. Prior studies found the gastric bacterial difference among gastritis, intestinal metaplasia and gastric cancer. However, they didn't reach an agreement. Correa's model is widely accepted in the development of gastric cancer. The pathological change makes a more suitable environment for bacteria to overgrowth. This study are designed to analyze the gastric microbial difference of non-atrophic gastritis, atrophic gastritis, intestinal metaplasia, intraepithelial neoplasia and gastric cancer.
Incidence of Pancreatic Fistula After Radical Gastrectomy
Gastric CancerPancreatic Fistula1 moreThis study is designed to investigate the incidence of pancreatic fistula after radical gastrectomy in gastric cancer patients.
Potential Clinical Utilities of Circulating Tumor DNA in Gastric Cancer
Gastric CancerThis study is designed to evaluate the potential clinical utility of ctDNA in the field of gastric cancer treatment,especially the usage of an indicator of MRD(minimal residual disease) in post radical gastrectomy patients. The primary purpose of this trial is to demonstrate if the postoperative ctDNA analysis could be used as an indicator of MRD or adjuvant chemotherapy response in advanced gastric cancer after radical gastrectomy.The second purpose is to describe the profile of ctDNA in gastric cancer.